Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14051 - 14075 of 14778 in total

(1R,2R)-N-(2-Aminoethyl)-2-{[(4-methoxyphenyl)sulfonyl]methyl}cyclohexanecarboxamide

Experimental

Cambendazole

Experimental
Vet approved

CG-200745

Cg200745 has been used in trials studying the treatment of Solid Tumour.
Investigational

IDM-2

IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
Matched Description: … from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and …

GPI-0100

GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy.
Investigational
Matched Description: … with a variety of vaccines, has been shown to have good overall performance characteristics on safety and …

AZD-8186

AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).
Investigational
Matched Description: … AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel …

BMS-986104

BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and …

Methyl 4,6-O-[(1R)-1-carboxyethylidene]-beta-D-galactopyranoside

Experimental

MF268

Experimental

Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]

Experimental

Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-Pyrimidine

Experimental

3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol

Experimental

(R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol

Experimental

6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE

Experimental

4-AMINO-2-TRIFLUOROMETHYL-5-HYDROXYMETHYLPYRIMIDINE PYROPHOSPHATE

Experimental

N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine

Experimental

2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE

Experimental

N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine

Experimental

Benzylfentanyl

Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM...
Illicit

2,6-Diamino-8-(1h-Imidazol-2-Ylsulfanylmethyl)-3h-Quinazoline-4-One

Experimental

Pyrithiamine Pyrophosphate

Experimental

3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL

Experimental

(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid

Experimental

(R)-Praziquantel

(R)-Praziquantel is under investigation in clinical trial NCT02271984 (Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers).
Investigational

Lorcainide

Experimental
Displaying drugs 14051 - 14075 of 14778 in total